[1-(4-hydroxyphenyl)-2-pyrrol-1-yl-1H-indol-3-yl]carbamic acid tert-butylester | 1191389-01-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: [1-(4-hydroxyphenyl)-2-pyrrol-1-yl-1H-indol-3-yl]carbamic acid tert-butylester
• 英文别名: tert-butyl N-[1-(4-hydroxyphenyl)-2-pyrrol-1-ylindol-3-yl]carbamate
• CAS: 1191389-01-1
• 化学式: C₂₃H₂₃N₃O₃
• 分子量: 389.454
• InChiKey: UOKMSWBOZPTLDX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  68.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] NOVEL ESTROGEN RECEPTOR LIGANDS<br/>[FR] NOUVEAUX LIGANDS DU RÉCEPTEUR D'OETROGÈNE
  申请人：KAROBIO AB

  公开号：WO2009127686A1

  公开（公告）日：2009-10-22

  The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate, and a solvate of such an ester, amide, carbamate or salt. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity, wherein R1, R2, R3, R4, R5 and R6 are as defined in the specification.

  本发明提供了一种公式(I)的化合物，或其药用可接受的酯、酰胺、碳酸酯、溶剂化物或盐，包括此类酯、酰胺或碳酸酯的盐，以及此类酯、酰胺、碳酸酯或盐的溶剂化物。本发明还提供了将此类化合物用于治疗或预防与雌激素受体活性相关的疾病或障碍的方法，其中R1、R2、R3、R4、R5和R6按说明书定义。
• NOVEL ESTROGEN RECEPTOR LIGANDS
  申请人：Rhönnstad Patrik

  公开号：US20110190294A1

  公开（公告）日：2011-08-04

  The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate, and a solvate of such an ester, amide, carbamate or salt. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity, wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the specification.

  本发明提供了式(I)的化合物或其药学上可接受的酯、酰胺、氨基甲酸酯、溶剂化物或盐，包括这种酯、酰胺或氨基甲酸酯的盐和这种酯、酰胺、氨基甲酸酯或盐的溶剂化物。本发明还提供了这种化合物在治疗或预防与雌激素受体活性相关的疾病或障碍的情况下的使用，其中R1、R2、R3、R4、R5和R6如规范中所定义。
• Novel Estrogen Receptor Ligands
  申请人：Rhonnstad Patrik

  公开号：US20130131061A1

  公开（公告）日：2013-05-23

  The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate, and a solvate of such an ester, amide, carbamate or salt. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity, wherein R 1 , R 2 , R 3 , R 5 and R 6 are as defined in the specification.

  本发明提供了化合物(I)或其药学上可接受的酯、酰胺、氨基甲酸酯、溶剂化物或盐，包括这种酯、酰胺或氨基甲酸酯的盐，以及这种酯、酰胺、氨基甲酸酯或盐的溶剂化物。本发明还提供了这些化合物在治疗或预防与雌激素受体活性相关的疾病或疾病相关障碍的条件中的使用，其中R1、R2、R3、R5和R6如规范中所定义。
• Estrogen receptor ligand treatment for neurodegenerative diseases
  申请人：The Regents of the University of California

  公开号：US10758496B2

  公开（公告）日：2020-09-01

  The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ERβ) ligand.

  本发明涉及使用雌激素受体β（ERβ）配体治疗神经系统疾病，如多发性硬化症（MS）和阿尔茨海默病。
• ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES
  申请人：The Regents of the University of California

  公开号：EP3189026A1

  公开（公告）日：2017-07-12